SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

Search

Sanofi SA

Cerrado

Sector Salud

103.98 0.48

Resumen

Variación precio

24h

Actual

Mínimo

103.92

Máximo

104.04

Métricas clave

By Trading Economics

Ingresos

-2.3B

499M

Ventas

-6.5B

7.6B

P/B

Media del Sector

23.481

73.394

BPA

1.31

Rentabilidad por dividendo

3.63

Margen de beneficio

6.539

Empleados

82,878

EBITDA

-3.7B

563M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+10.19 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.63%

3.09%

Próximas Ganancias

24 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.1B

130B

Apertura anterior

103.5

Cierre anterior

103.98

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

109 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2025, 13:41 UTC

Ganancias

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5 feb 2025, 07:10 UTC

Ganancias

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5 feb 2025, 06:39 UTC

Ganancias

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

19 feb 2025, 06:35 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 feb 2025, 06:34 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 feb 2025, 06:34 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 feb 2025, 06:32 UTC

Adquisiciones, fusiones, absorciones

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 feb 2025, 06:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi, CD&R Sign Opella Share Purchase Agreement

14 feb 2025, 10:55 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5 feb 2025, 07:48 UTC

Charlas de Mercado
Ganancias

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

5 feb 2025, 06:01 UTC

Ganancias

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

5 feb 2025, 06:01 UTC

Ganancias

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

5 feb 2025, 06:00 UTC

Ganancias

Santander Names Juan Franco as New Global CEO of Getnet Payments Business

5 feb 2025, 05:59 UTC

Ganancias

Santander: Buyback to Run From Feb. 6 to June 27

5 feb 2025, 05:58 UTC

Ganancias

Santander: Regulatory Authorization for New Buyback Program Has Already Been Obtained

5 feb 2025, 05:55 UTC

Ganancias

Santander 4Q-End Fully-Loaded CET1 Ratio 12.8%

5 feb 2025, 05:53 UTC

Ganancias

Santander 4Q Net Fee Income EUR3.34B

5 feb 2025, 05:53 UTC

Ganancias

Santander 4Q Net Interest Income EUR11.99B

5 feb 2025, 05:53 UTC

Ganancias

Analysts Saw Santander 4Q Revenue at EUR15.39B

5 feb 2025, 05:53 UTC

Ganancias

Analysts Saw Santander 4Q Net Profit at EUR2.95B

5 feb 2025, 05:52 UTC

Ganancias

Santander 4Q Net Pft EUR3.265B

5 feb 2025, 05:52 UTC

Ganancias

Santander 4Q Rev EUR16.03B

5 feb 2025, 05:51 UTC

Ganancias

Santander Previously Targeted 2025 Return on Tangible Equity of 15%-17%

5 feb 2025, 05:50 UTC

Ganancias

Santander Targets 2025 Return on Tangible Equity of More Than 17%

5 feb 2025, 05:49 UTC

Ganancias

Santander Targeting Mid-High Single Digit Growth in 2025 Net Fee Income

5 feb 2025, 05:49 UTC

Ganancias

Santander Sees 2025 Rev EUR62B

5 feb 2025, 05:48 UTC

Ganancias

Santander Expects to Return EUR10B to Shareholders Through Buybacks from 2025 and 2026

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

10.19% repunte

Estimación a 12 meses

Media 114.73 EUR  10.19%

Máximo 125 EUR

Mínimo 92 EUR

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

9

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

103.4 / 104.88Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

109 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.